









Markets
/
Stocks
/
nasdaq-qlgn
/

Qualigen Therapeutics Inc

QLGN

2.520USD

-0.290-10.32%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

4.12MMarket Cap

LossP/E TTM



Qualigen Therapeutics Inc

2.520

-0.290-10.32%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Qualigen Therapeutics Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Qualigen Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

236 / 407

Overall Ranking

470 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Qualigen Therapeutics Inc Highlights

StrengthsRisks

Qualigen Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing treatments for adult and pediatric cancers. The Company’s business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS). Its lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells (such as pancreatic cancer). Its Pan-RAS program, which is at the preclinical stage, consists of a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules inhibits or block mutated RAS genes’ proteins from binding to their effector proteins thereby leaving the proteins from the mutated RAS unable to cause further harm. Its QN-302 is in a Phase 1a clinical trial.

Overvalued

The company’s latest PE is 0.36, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 18.02K shares, decreasing 42.57% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 314.00 shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.93.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 6.25, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.25

Change



Financials

7.55

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.23

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.79

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

6.87

Key Metrics

Free cash flow

No Data

Qualigen Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 6.52, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is 0.36, which is 138.50% below the recent high of 0.86 and 834.07% above the recent low of -2.65.

Score

Industry at a Glance

Previous score

6.52

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 236/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 5.41, which is lower than the Biotechnology & Medical Research industry's average of 6.41. Sideways: Currently, the stock price is trading between the resistance level at 4.83 and the support level at 1.35, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.32

Change

0.09

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.307

Sell

RSI(14)

35.969

Neutral

STOCH(KDJ)(9,3,3)

3.289

Oversold

ATR(14)

0.543

High Vlolatility

CCI(14)

-107.926

Sell

Williams %R

99.281

Oversold

TRIX(12,20)

-1.379

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

2.818

Sell

MA10

3.033

Sell

MA20

3.533

Sell

MA50

3.372

Sell

MA100

3.087

Sell

MA200

3.286

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 0.89%, representing a quarter-over-quarter decrease of 50.29%. The largest institutional shareholder is The Vanguard, holding a total of 314.00 shares, representing 0.02% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Alpha Capital Aktiengesellschaft

36.43K

+33.46%

Geode Capital Management, L.L.C.

5.26K

Tower Research Capital LLC

1.19K

+217.65%

BlackRock Institutional Trust Company, N.A.

511.00

Harbour Investments, Inc

325.00

The Vanguard Group, Inc.

Star Investors

314.00

HighMark Wealth Management LLC

160.00

Raymond James & Associates, Inc.

20.00

Raymond James Financial Services Advisors, Inc.

10.00

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 1.19, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.28. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.